About Us

Gifford Bioscience is a preclinical contract research organization (CRO) providing services in radioligand binding assays, receptor affinity and occupancy studies and autoradiography.

We are a premium provider. We adhere tightly to our core specialism and our scientists all hold PhD’s.

We undertake standard or custom assays on our customer’s samples to our customer’s specification. Additional capabilities include assay design, cell culture, in-house production of membrane preparations and assays requiring human or animal tissue. 

We are based at The BioHub Birmingham, on the University of Birmingham’s research park. We maintain strategic relationships with the University for access to its Human Biomedical Resource Centre, Protein Expression Facility and Biomedical Services Unit.

CONTACT US for a chat. We are always happy to discuss potential requirements and assay design.

“Thank you for a very well executed study and a high quality report which you delivered efficiently, we do appreciate it.”

Senior Director of Research, Californian Pharma, Apr 2023

An international customer base:

50% of our clients are in the USA. A further quarter are based in the EU.


“The service was very good, turnaround time was very efficient and the data were well presented. In particular, the communication with Kevin and Becky was very clear. We would definitely recommend your services to others.”

CTO, UK Biotech, Apr 2023

“I would like thank you, Macer, Sian and your Team for the extremely fast and excellent work. We appreciate it a lot. The data and report are all clear.”

Scientist, Swiss Life Sciences Institute, Jan 2023

88% of our business is repeat business, coming from the scientists we have worked with before.


“Your service has been great  – good communications – skilled scientists- quality data and presentations ;O).”

Principal Scientist, Big Pharma, Denmark, Dec 2022

“Excellent work, high quality, very thorough and diligent. Love working with Gifford.”

Director Biology, Californian Biotech, Aug 2022

“We particularly appreciate the way your experienced scientists engage in scientific discourse with us, ensuring the optimal use of radioligand binding assays. Grateful for the excellent overall service.”

Associate Professor, East Coast University School of Medicine, Aug 2022

“We are so impressed with your serious scientific discussion, professional advice, and excellent service. We would like to commission many experiments with our other pipeline in the future, and I promise to introduce Gifford to many other groups. Thanks to all of you!”

Principal Researcher, Korean Biotech, 2021

“I am really impressed how fast and professionally you act. 😊. It is clear to me that you at Gifford like ‘doing science’ and challenges.”

Principal Scientist, German Pharma, 2021

The Management Team

Dr Andrew Gifford 

Chairman and Chief Scientific Officer

Andrew was previously a Senior Scientist in the radiopharmaceutical development program at Brookhaven National Laboratory, New York. As a Principal Investigator, he has been responsible for the preclinical development of a variety of radiolabeled drugs. Techniques employed in his academic laboratories were primarily radiometric ligand binding and occupancy assays, radiolabeling chemistry and autoradiography.

Andrew is a graduate of Imperial College, London and was awarded his PhD in Pharmacology by the University of St. Andrews.

He is an author of 52 peer-reviewed publications.

Mr Macer Gifford

Managing Director

Macer is a banker by profession. His 25 year career in finance has spanned numerous senior roles. Most recently, he was Deputy Group CEO at Ahli United Bank. Macer was previously a Managing Director then Group Head at Standard Chartered PLC, where he assumed overall responsibility for the management of the Group’s balance sheet.

Macer is a graduate of the London School of Economics and a Sloan Fellow of the London Business School.

Dr Kevin Thompson

Chief Operating Officer

Kevin has a wealth of industry experience, encompassing both sides of the big pharma (Knoll Pharmaceutical) / CRO (BioFocus) relationship. In his 25 year career, Kevin has also worked for several biotechs: he joined Gifford Bioscience in 2019 from Chronos Therapeutics, where he was director of Screening and Operations. Kevin has a deep knowledge of in vitro screening applied to diverse therapeutic targets. He uses his in-depth understanding of binding kinetics to oversee our SPR (Biacore) assay services.

Kevin is a Biology graduate and was awarded his DPhil in Neurobiology, both at Sussex University.

He is an author of 31 peer-reviewed publications.

Contact Us

    OBN Members Badge Image

    Copyright © 2023 Gifford Bioscience Limited
    Privacy Policy

    Copyright © 2023 Gifford Bioscience Limited
    Privacy Policy